Please login to the form below

Not currently logged in
Email:
Password:

Boehringer partners with US universities

Will work with Yale and Vanderbilt on cancer projects
Boehringer headquarters

German pharma company Boehringer Ingelhiem has entered research collaborations with two leading universities in the US.

The company will work with Yale University in Connecticut and Vanderbilt University in Tennessee on separate programmes to develop new medicines.

The deal with Yale University will see the partners collaborate on developing immunotherapies, medicines that encourage the body's immune system to fight a disease.

Research will cover several therapeutic areas, including oncology, autoimmune and respiratory disorders.

The project will be led by Dr Lieping Chen, director of cancer immunology at the Yale Cancer Center, who has experience in the growing area of anti-PD-1 medicines.

"This collaboration will help us to identify important pathways, and what the biological application of modulating those pathways will be," said Dr Chen. "We will investigate whether these new pathways could become future drug targets."

The partnership with Vanderbilt University has cancer as its main focus, specifically the research of inhibitors of the gene Ras, which when mutated can lead to the development of cancer.

According to Boehringer Ras is the most frequently mutated gene known in cancer. There are several mutations known as H-Ras, N-Ras and K-Ras and mutations in the Ras family are found in 20% to 30% of all human tumours.

However, despite the commonality of the mutation, Ras has been a particularly difficult protein to target since its discovery in human cancers more than 30 years ago.

Dr Michel Pairet, senior corporate VP of research and non-clinical development at Boehringer Ingelheim, said: “We believe that our combined strengths and philosophies in drug discovery will go a long way in addressing what has up to now been a very difficult drug target.”

Article by
Thomas Meek

15th January 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics